Cargando…

Immunotherapeutic Strategies in the Management of Osteosarcoma

Osteosarcoma (OS) is the most common primary malignant bone cancer with a high tendency for metastasis. Although treatment strategies involving surgery and chemotherapy have improved outcomes for patients with OS, the prognosis of recurrent OS is quite unsatisfactory. Primary reasons leading to mort...

Descripción completa

Detalles Bibliográficos
Autores principales: Supra, Rajiv, Agrawal, Devendra K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018813/
https://www.ncbi.nlm.nih.gov/pubmed/36937115
http://dx.doi.org/10.26502/josm.511500076
_version_ 1784907890509742080
author Supra, Rajiv
Agrawal, Devendra K
author_facet Supra, Rajiv
Agrawal, Devendra K
author_sort Supra, Rajiv
collection PubMed
description Osteosarcoma (OS) is the most common primary malignant bone cancer with a high tendency for metastasis. Although treatment strategies involving surgery and chemotherapy have improved outcomes for patients with OS, the prognosis of recurrent OS is quite unsatisfactory. Primary reasons leading to mortality in OS patients are resistance to currently used therapies and the subsequent lung metastasis. Immunotherapy, however, has been shown to be a promising therapeutic strategy against OS. As research progresses, immunotherapy is gradually becoming irreplaceable. This article provides a critical evaluation of several therapeutic strategies for OS including immunomodulation, vaccine therapy, and immunologic checkpoint blockade.
format Online
Article
Text
id pubmed-10018813
institution National Center for Biotechnology Information
language English
publishDate 2023
record_format MEDLINE/PubMed
spelling pubmed-100188132023-03-16 Immunotherapeutic Strategies in the Management of Osteosarcoma Supra, Rajiv Agrawal, Devendra K J Orthop Sports Med Article Osteosarcoma (OS) is the most common primary malignant bone cancer with a high tendency for metastasis. Although treatment strategies involving surgery and chemotherapy have improved outcomes for patients with OS, the prognosis of recurrent OS is quite unsatisfactory. Primary reasons leading to mortality in OS patients are resistance to currently used therapies and the subsequent lung metastasis. Immunotherapy, however, has been shown to be a promising therapeutic strategy against OS. As research progresses, immunotherapy is gradually becoming irreplaceable. This article provides a critical evaluation of several therapeutic strategies for OS including immunomodulation, vaccine therapy, and immunologic checkpoint blockade. 2023 2023-02-06 /pmc/articles/PMC10018813/ /pubmed/36937115 http://dx.doi.org/10.26502/josm.511500076 Text en https://creativecommons.org/licenses/by/4.0/This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license 4.0
spellingShingle Article
Supra, Rajiv
Agrawal, Devendra K
Immunotherapeutic Strategies in the Management of Osteosarcoma
title Immunotherapeutic Strategies in the Management of Osteosarcoma
title_full Immunotherapeutic Strategies in the Management of Osteosarcoma
title_fullStr Immunotherapeutic Strategies in the Management of Osteosarcoma
title_full_unstemmed Immunotherapeutic Strategies in the Management of Osteosarcoma
title_short Immunotherapeutic Strategies in the Management of Osteosarcoma
title_sort immunotherapeutic strategies in the management of osteosarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018813/
https://www.ncbi.nlm.nih.gov/pubmed/36937115
http://dx.doi.org/10.26502/josm.511500076
work_keys_str_mv AT suprarajiv immunotherapeuticstrategiesinthemanagementofosteosarcoma
AT agrawaldevendrak immunotherapeuticstrategiesinthemanagementofosteosarcoma